Skip to content

TANGHE PHARMA

Active Private limited companyfounded 2012active for 14 yearsVollezelestraat 25, 1755 PajottegemKBO/BCE: BE 0848.766.826

Lifetime

12 annual accounts with figures on one time axis
peak of €218,085 in 2014
€167,075▲ 3.2%
peak of €112,735 in 2014
€56,475▼ 1.6%
peak of €702,112 in 2023
€542,365▼ 5.8%
€950,726▼ 4.1%
Board1 name since 2012
1 director
Documentsfilings and deeds
26-01-20265 days before the deadline
2025abbreviated format
Dividend €89,683Cash from €13,291 to €2,150

Key points

from the 2025 annual accounts

Equity

€542,365 ▼ 5.8%
575,5732024+56,475Profit-89,683Dividend542,3652025

TANGHE PHARMA paid out €89,683 in dividends. That is 159% of the 2025 profit.

Turnover

≈ €270,000 estimated

The abbreviated format states no turnover.

Filings

12 annual accounts since 2014
deadline201520202025

The 2020 accounts came 1 day late. The other nine of the last ten were filed on time.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 6,059 companies had the same profile as TANGHE PHARMA has now. Each dot stands for 16 companies, two years later.

95.8%
were still trading
3.7%
stopped another way
0.4%
went bankrupt
  • Small
  • 10 to 20 years old
  • solvency 30% or more
  • a profit under 5% of the balance sheet
Test of the method

The method was tested on the 498,062 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.7% would go bankrupt within 24 months. In fact 1.8% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.4% 0.5%
3 0.6% 0.6%
4 0.7% 0.8%
5 0.9% 1.0%
6 1.4% 1.6%
7 1.7% 1.8%
8 1.9% 2.0%
9 3.1% 3.3%
10 5.9% 6.4%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 6,059 companies, not a prediction for TANGHE PHARMA. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Director, since 16-09-2012
  • founderdeed of 20-09-2012
Board & ownership

Recent changes

Environmental permit granted Convert or extend · decided by Halle
Registered in the Peppol Directory Reachable for e-invoices through 0208:0848766826
changes role from manager to director Legal-form conversion: from private limited company (pre-2019) to private limited company · General meeting of 16-10-2023 · Gazette deed
Incorporation Founding capital of €18,550, 100 shares, €12,400 paid up · Founded by · appointed as manager · published on 20-09-2012 · Gazette deed
All 21 events

Comparable companies

same main activity, similar in size and age
Company
TANGHE PHARMA Pajottegem €1.5m €167,075 36.3% -
LIVATO GROUP Diest €1.6m €142,133 51.3% 1
AIR MANAGEMENT Zonnebeke €1.4m €159,689 25.4% -
DADIST Beernem €1.5m €171,995 33.7% -
TYGRA Kortrijk €1.7m €177,650 68.8% 1
JENS Roeselare €1.9m €171,797 20.8% -
VERCLI Kortrijk €1.2m €153,902 23.1% -

These companies have the same main activity as TANGHE PHARMA: activities of head offices (NACE 70100). They are comparable in size and age: total assets between €1.2m and €1.9m, founded between 2011 and 2014.

Official details

Source: KBO
Status
Active since 18-09-2012Normal situation
Activity
Activities of head officesNACE 70100and 3 others
Establishment unit
2.215.131.4911755 Pajottegem, since 18-09-2012
Financial year end
30 June
Peppol
Reachable since 02-12-2025
Company details

Annual accounts to 30-06-2025

€1.5m▼ 4.7%
Filing
Filed on 26-01-2026, 5 days before the end of the filing period
Financials

Insights on TANGHE PHARMA

TANGHE PHARMA files the abbreviated format. That format states no turnover. The gross margin fell from €218,085 in 2014 to €167,075 in 2025.

The balance sheet grew most from 2015 to 2017 through fixed assets.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about TANGHE PHARMA

What is the company number of TANGHE PHARMA?
The company number of TANGHE PHARMA is 0848.766.826. The VAT number is the same number with BE in front: BE 0848.766.826.
Where is TANGHE PHARMA based?
The registered office is at Vollezelestraat 25, 1755 Pajottegem.Company details
What does TANGHE PHARMA do?
According to the KBO register, the main activity is activities of head offices (NACE 70100).
What is the legal form of TANGHE PHARMA?
TANGHE PHARMA is a private limited company (BV).
When was TANGHE PHARMA founded?
TANGHE PHARMA was founded on 18-09-2012.
Is TANGHE PHARMA still active?
Yes, TANGHE PHARMA is an active enterprise in the KBO register.
What is the turnover of TANGHE PHARMA?
The turnover in financial year 2025 is about €270,000. This figure is estimated from the gross margin of €167,075 and 84 comparable companies (NACE 70). It probably lies between €220,000 and €390,000.Financials
Is TANGHE PHARMA profitable?
In financial year 2025, TANGHE PHARMA made a profit of €56,475.
Where can I find the annual accounts of TANGHE PHARMA?
TANGHE PHARMA filed 12 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of TANGHE PHARMA due?
TANGHE PHARMA must file the annual accounts for financial year 2026 by 31-01-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.